Use of generic cardiovascular medications by elderly medicare beneficiaries receiving generalist or cardiologist care

Medical Care

Volumn 45, Issue 2, 2007, Pages 109-115

  Federman, Alex D ^a   Halm, Ethan A ^a   Siu, Albert L ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiologist; Cardiovascular disease; Elderly; Generalist; Generic drugs; Medicare

Indexed keywords

CARDIOVASCULAR AGENT; GENERIC DRUG;

AGED; ARTICLE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; FEMALE; GENERAL PRACTICE; HEALTH INSURANCE; HUMAN; MALE; MEDICARE;

AGED; AGED, 80 AND OVER; CARDIOLOGY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; DRUGS, GENERIC; FAMILY PRACTICE; FEMALE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33846427527     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000250293.24939.2e     Document Type: Article

References (33)

1. Piette JD, Heisler M, Wagner TH. Cost-related medication under-use: do patients with chronic illnesses tell their doctors? Arch Intern Med. 2004;164:1749-1755.
2. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94:1782-1787.
3. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood). 2005;Supp(Web Exclusives):W152-W166.
4. Wilson IB, Rogers WH, Chang H, et al. Cost-related skipping of medications and other treatments among Medicare beneficiaries between 1998 and 2000. Results of a national study. J Gen Intern Med. 2005;20:715-720.
5. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA. 2003;290:953-958.
6. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18:201-212.
7. Shrank W, Hoang T, Ettner S, et al. The implications of choice: prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med. 2006;166:332-337.
8. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051-1063.
9. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13:207-214.
10. Haas JS, Phillips KA, Gerstenberger EP, et al. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142:891-897.
11. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
12. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Aff (Millwood). 2003;22:149-158.
13. Joyce GF, Escarce JJ, Solomon MD, et al. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733-1739.
14. Shrank WH, Young HN, Ettner SL, et al. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care. 2005;11:16-22.
15. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351:2187-2194.
16. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662-674.
17. Banahan BF 3rd, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080-2088.
18. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000;160:2799-2803.
19. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
20. Ferguson RP, Rhim E, Belizaire W, et al. Encounters with pharmaceutical sales representatives among practicing internists. Am J Med. 1999;107:149-152.
21. Spiller LD, Wymer WW Jr. Physicians' perceptions and uses of commercial drug information sources: an examination of pharmaceutical marketing to physicians. Health Mark Q. 2001;19:91-106.
22. Caudill TS, Johnson MS, Rich EC, et al. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5:201-206.
23. Tamblyn R, McLeod P, Hanley JA, et al. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003;41:895-908.
24. Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev. 1994;15:153-163.
25. VA Pharmacy Formulary Analysis Committee, Division of Health Care Services, Institute of Medicine. Description and analysis of the VA National Formulary. Washington, DC: National Academy Press; January 2000.
26. U.S. Food and Drug Administration Orange Book. Available at: http://www.fda.gov/cder/ob/docs/queryai.htm. Accessed October 16, 2006.
27. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
28. Murphy JE. Generic substitution and optimal patient care. Arch Intern Med. 1999;159:429-433.
29. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-689.
30. Kaplan SH, Greenfield S, Gandek B, et al. Characteristics of physicians with participatory decision-making styles. Ann Intern Med. 1996;124:497-504.
31. Roter DL, Stewart M, Putnam SM, et al. Communication patterns of primary care physicians. JAMA. 1997;277:350-356.
32. Poisal JA. Reporting of drug expenditures in the MCBS. Health Care Financ Rev. 2004;25:1-4.
33. Kravitz RL, Chang S. Promise and perils for patients and physicians. N Engl J Med. 2005;353:2735-2739.